HRH1 and melanoma: Experimentally, in colorectal cancer and melanoma cell models, inhibition of the histamine H1 receptor in macrophages can restore T-cell antitumor immunity, demonstrating that patients with cancer receiving H1 antihistamines concurrently with ICIs experienced improved OS (5).